BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 29
• 30
• 31

• Press Releases

  ViroCell Biologics Expands U.S. Business Development Team With Two New Appointments

  December 16, 2024

   · 

  3 min read
• Press Releases

  PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial

  December 16, 2024

   · 

  15 min read
• 

  Press Releases

  Simcere’s Sanbexin Emerges as Game-Changer: FDA Grants Breakthrough Therapy Designation to Sanbexin for AIS Treatment

  December 16, 2024

   · 

  5 min read
• Press Releases

  SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (HFMD)

  December 16, 2024

   · 

  2 min read
• Press Releases

  Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development

  December 16, 2024

   · 

  2 min read
• Press Releases

  Serina Therapeutics to Present at Tribe Public’s Webinar Event “Enabling Continuous Drug Delivery for Parkinson’s Disease & Beyond” on Wednesday, December 18, 2024

  December 16, 2024

   · 

  4 min read
• Press Releases

  IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers

  December 16, 2024

   · 

  4 min read
• Press Releases

  Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)

  December 16, 2024

   · 

  14 min read
• Press Releases

  Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC

  December 16, 2024

   · 

  19 min read
• Press Releases

  Amarin Receives National Reimbursement for VAZKEPA® in Italy

  December 16, 2024

   · 

  6 min read